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Abstract
Immunity against the pre-erythrocytic stages of malaria is the most promising, as it is strong and fully sterilizing.
Yet, the underlying immune effectors against the human Plasmodium falciparum pre-erythrocytic stages remain
surprisingly poorly known and have been little explored, which in turn prevents any rational vaccine progress.
Evidence that has been gathered in vitro and in vivo, in higher primates and in humans, is reviewed here,
emphasizing the significant role of IFN-g, either as a critical immune mediator or at least as a valuable surrogate
marker of protection. One may hope that these results will trigger investigations in volunteers immunized either by
optimally irradiated or over-irradiated sporozoites, to quickly delineate better surrogates of protection, which are
essential for the development of a successful malaria vaccine.
Background
Immunity to the pre-erythrocytic stages of malaria (i.e.
sporozoite and liver stages), which can be best induced
following immunization with radiation-attenuated para-
sites at sporozoite stage, is unusual in many respects
[1-3]. Indeed, it is a very strong, fully sterilizing immu-
nity, and this stands in contrast to immunity to other
stages of Plasmodium. Since this immunity specifically
targets the asymptomatic pre-erythrocytic stage, which
precedes the pathogenic blood stages, it can ensure a
full prophylaxis suitable for travellers and has, therefore,
attracted the vast majority of malaria vaccine funding.
Yet, the immune effectors underlying such a strong
pre-erythrocytic immunity,a sw e l la st h et a r g e ts p o r o -
zoite and liver stage (LS) antigens, remain surprisingly
poorly known, at least in the case of Plasmodium falci-
parum in humans [4,5]. Thus, the paradox is that the
most promising and effective vaccine against malaria
relies on mechanisms which are not identified, nor even
searched for. The lack of an immunological basis for
protection against P. falciparum pre-erythrocytic stages
is, in turn, inhibiting any rational progress with the few
vaccine candidates under development, and the identifi-
cation of better candidates [6].
Conversely, over the past 30 years there have been
extensive studies conducted using rodent malaria species
in laboratory models. These studies have, in a way,
added to the confusion by demonstrating a plethora of
very effective mechanisms, ranging from sporozoite-
neutralizing antibodies to cell-mediated immunity and
its various effectors, though without providing a single
clue as to which of them would be critical against
P. falciparum [7].
The difficulties are related to the diversity of the mod-
els employed, their relevance and the strong efficacy of
each immune effector investigated in one or the other
model [8]. Indeed, numerous studies have demonstrated
a role for antibody responses in protection, both under
in vitro and under in vivo conditions. In this case, many
antibody-mediated mechanisms have been demonstrated
including detachment of the sporozoite surface ("cir-
cumsporozoite precipitation”) [9], opsonization [10],
ADCC [11], inhibition of sporozoite invasion and inhibi-
tion of intra-hepatic development [12,13]. Conversely,
MHC expression by the host cell, the hepatocyte, has
understandably led to analysis and description of the
potent effects of various T-cell subsets [14-18]. Studies,
both in vitro and in vivo, have established by selective
depletion [19-22], knock-outs or adoptive transfer
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any medium, provided the original work is properly cited.[16,23-26], the role of mainly CD8 cells but also CD4
T-cells (reviewed in [27]), gδ T-cells [28], NK [29,30]
and NKT-cells [31], or stellate (Ito) cells [32], thought
to act either directly (e.g. by a CTL effect) or indirectly
either by their mediators or T-cell driven recruitment of
inflammatory cells, predominantly polymorphs macro-
phages and Kuppfer cells. Among the many immune
mediators in which a protective effect was reported, the
most potent are interleukin 12 (IL12) [33], interferon
gamma (IFN-g) [20,34-36], O2- [37], and NO radicals,
but also, NO synthase [38-40], TNF [41,42], IL1 [35],
IL6 [43] leading to the secretion of C-reactive protein
[44], hemopexin, a1-anti-trypsin and a2-macroglobulin
to name but a few, whose ability to block liver schizog-
ony was reported as being highly effective [45].
The diversity of immune effectors also reflects the
diversity of the host-parasite combinations in which
they were described. Indeed the combination of each of
the rodent Plasmodium with each of the many available
inbred mice strains, or the natural host the tree-rat
Thamnomys, constitute a plethora of situations, which
differ from each other and in which the main effector
also differs [7,46,47]. A main bottleneck with those
models is to determine which of them, if any, is relevant
to the human-P. falciparum situation. This essential
issue remains unresolved. After over three decades of
investigations in animal models, the question: “what
would be the most likely protective immune effector and
surrogate marker of protection relevant to the human-P.
falciparum situation“ remains open and unresolved.
Results from such models are thus at best indicative,
and at worst irrelevant, and therefore can be misleading
[8,46]. This is demonstrated by the large variety of vac-
cine formulations that induce those immune-effectors
which proved highly effective at protecting rodents, yet
failed when evaluated in human clinical trials [48-50].
The immune effectors responsible for protection in
humans remain unknown, to the extent of being unable
to clarify the simplest dichotomy of whether it is mainly
dependant on either “antibody” or on “T-cells”,a tl a r g e
(reviewed in [4,5,51]).
Previous work with P. falciparum irradiated sporo-
zoites, and P. falciparum-derived vaccine formulations,
particularly liver stage antigen-3 (LSA3) [52], has consis-
tently pointed to IFN-g as a marker associated with pro-
tection against P. falciparum pre-erythrocytic stage. The
present paper reviews the few available in vitro results
and more abundant in vivo findings in non-human pri-
mate models (according to methods which are described
in the references quoted below) that document this mat-
ter, and highlight how these findings are consistent with
reports in humans.
Given the limitations of the rodent models mentioned
above, only observations previously made with
P. falciparum are mentioned, to highlight more clearly
than previous reports the critical role of IFN-g as either
a critical immune mediator or at least a valuable surro-
gate marker of protection.
IFN-g: a critical immune mediator and/or surrogate
marker of protective immunity against P. falciparum pre-
erythrocytic stages
Results supporting a critical role of IFN-g in protective
immunity against P. falciparum pre-erythrocytic stages
come from studies conducted both in vitro and in vivo,
in chimpanzee, Aotus and, to some extent, in humans.
Data obtained in higher primates are particularly valu-
able, as several animals underwent multiple challenges.
Since all immunized animals were not protected this
situation provided an opportunity to compare responses
in protected versus non-protected challenges.
IFN-g inhibits P. falciparum liver schizogony in vitro
In vitro studies with P. falciparum in primary cultures of
human hepatocytes revealed a very potent effect of
IFN-g. Indeed, very low concentrations of IFN-g were
efficient against P. falciparum liver forms and moderate
concentrations were able to fully block the liver schizo-
gonic development. Concentrations of 1 and 10 IU/ml,
achieved respectively 90 and 100% inhibition of P. falci-
parum liver schizogony [35], and up to 40% inhibition
was still obtained at a concentration as low as 0.1 IU.
Subsequent studies confirmed the strong effect of IFN-g
though with minor differences in the extent of inhibition
obtained, possibly related either to the recombinant
IFN-g employed, or to experimental conditions. There-
after, IFN-g has been frequently included as a positive
control for in vitro drug or sporozoite inhibition studies
and results have reproduced the initial findings (unpub-
lished material).
IFN-g response is associated with protection in Aotus
monkeys
In a preliminary study, sterile protection against
P. falciparum sporozoites challenge (10
5 sporozoites IV)
was achieved in three out of five monkeys immunized
with a microparticulate vaccine formulation of LSA3,
without adjuvant [53]. Antibodies reacting with the
native parasite sporozoite protein were induced at low
titers, but were later boosted following sporozoite chal-
lenge. The LSA3-specific IFN-g secretion, measured
either by ELISpot or sandwich ELISA assays, was detect-
able in all LSA3 immunized animals. However, IFN-g
responses were significantly higher in protected versus
non-protected monkeys (Figure 1).
In a second study, monkeys were immunized using
two long LSA3 synthetic peptides formulated in the
ASO2 adjuvant [54]. Protection was achieved in all
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5 P. falciparum
sporozoites, in contrast to controls receiving the ASO2
adjuvant alone. Protection in monkeys immunized with
either one of the two LSA3 peptides was associated,
besides antibody responses, with strong IFN-g secretion
specific to the synthetic immunogen as well as to the
native protein. Though all animals of the 2
nd study were
protected, IFN-g secretion was at levels similar to those
measured in protected monkeys from the first study
(Figure 1).
IFN-g response is associated with protection in
chimpanzees
Three different LSA3 vaccine formulations were
assessed in the chimpanzee experimental challenge
model. A first group was immunized using a vaccine
formulation consisting of LSA3 recombinant proteins
delivered in ASO2 adjuvant [55]. The antibody responses
to different regions of the protein were homogeneously
high among both protected and non-protected animals,
providing no predictive indication of protection. In con-
trast, IFN-g production was markedly higher in the pro-
tected chimpanzees (Cyndi and Wendy) compared to
non-protected chimpanzees (Marti and Willy) (Figure 2).
This was true when considering responses from lympho-
cytes challenged in vitro by either LSA3 recombinant
antigens or by synthetic peptides (Figure 2).
A second group of chimpanzees was immunized with
a vaccine formulation consisting of two LSA3 lipopep-
tides, delivered in adjuvant-free saline, and a third LSA3
peptide mixed with montanide adjuvant [55]. Very
strong B and T-helper cell responses were observed,
and all peptides induced the secretion of IFN-g,w i t h
the highest responses directed to the peptide from the
non-repeated N-terminal region. Consistent with results
obtained in Aotus monkeys, markedly higher IFN-g
levels were observed among chimpanzees showing pro-
tection upon challenge (Gerda, Dirk, Mopia, Mgbado),
as compared to unprotected animals (Iris, Karlien). The
above pattern of immune responses investigated before
challenge correlated with protection observed in two
successive P. falciparum sporozoite challenges per-
formed at either moderate or very high sporozoites
challenge dose (20,000 and 1 million sporozoites
respectively).
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Figure 1 IFN-g is associated with protection induced by LSA3
in Aotus monkeys. Specific IFN-g responses were studied in nine
Aotus immunized either by LSA3 recombinant proteins [53] or by
long peptides [54]. Monkeys were challenged with P. falciparum
sporozoites from Santa lucia strain and the IFN-g responses were
evaluated in protected, non-protected and control animals
immunized with the GST or ASO2 adjuvant alone. After
immunization, the production of IFN-g was assessed either ex-vivo
by ELISpot or by ELISA after 40 h of in vitro re-stimulation with LSA3
peptides (squares) or Rc proteins (circles), as described in detail in
[53] and [55].
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Figure 2 IFN-g is associated with protection induced by LSA3
in chimpanzees. Summary of specific IFN-g responses in eighteen
chimpanzees immunized either by LSA3 recombinant proteins or by
Peptides/Lipopeptides. Chimpanzees were challenged once or twice
(*) with P. falciparum sporozoites. After immunization, the IFN-g
producing T cell responses were compared in protected versus non-
protected animals. Chimpanzees that received adjuvant alone or
saline alone (vehicle) were used as controls. The production of IFN-g
was assessed after in vitro stimulation with LSA3 peptides (squares)
or Rc proteins (circles) using either ELISA (A), as described [55] or ex-
vivo ELISpot (B) as described [53,56].
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following LSA3 immunization was not obtained in all
animals, it was hypothesized that combination of LSA3
with other pre-erythrocytic stage antigens may act
synergistically to result in higher levels of IFN-g and
better protection. Thus, in a subsequent experiment in a
third group of chimpanzees LSA3 was delivered in com-
bination with either LSA1, SALSA or STARP. Surpris-
ingly, the combined immunization led to over three-fold
decrease in LSA3-specific IFN-g responses. Indeed,
LSA3 alone yielded a mean IFN-g response of 108 ± 35
IU/ml, whereas the LSA3-specific IFN-g secretion
obtained with the antigen combinations was markedly
lower, either with LSA1 (35 ± 21 IU), STARP (16 ± 4
IU) or SALSA (2 ± 0,2 IU). This was associated with an
absence of protection as compared to animals receiving
LSA3 alone (Thomas A, Millet P et al,u n p u b l i s h e d
material). Hence, here again a relationship was observed
between the intensity of IFN-g response and protection.
These results also suggested a negative interaction
between antigens, which is noteworthy at a time when
indiscriminate antigen combinations are actively
promoted.
T h ed i f f e r e n c ei nI F N - g levels between protected and
non-protected chimpanzees was analysed by a non-
parametric median comparison test. The results showed
that IFN-g secretion was significantly higher among pro-
tected chimpanzees (p = 0.003). When post-immuniza-
t i o n ,p r e - c h a l l e n g e ,I F N - g responses were analysed with
respect to the outcome of all challenges performed in
those animals (as some underwent several successive
challenges), the correlation between IFN-g and protec-
tion was also significant (p = 0.0002). Conversely, the
antibody levels induced in chimpanzee using different
immunization protocols were not found to be associated
with protection (p = 0.3).
A fourth group of chimpanzees underwent genetic
immunization using P. falciparum LSA3-DNA [56]. Pro-
tection upon challenge was obtained in four out of six
immunized animals, and was reproducible upon a 2
nd
challenge performed five months later. Immune
responses induced by DNA vectors were as scarce in
chimpanzees as they were in humans, thereby stressing
the homology between these two closely related species.
For instance, specific antibodies were not detectable.
Conversely, positive IFN-g Elispot responses were
obtained in each of the LSA3-DNA immunized
chimpanzees, and IFN-g responses to several peptides was
associated with protection, i.e. present in protected ani-
mals, and absent in immunized-non-protected ones [56].
In the above studies, responses in chimpanzees were
specific to LSA-3 and were composed of both MHC
class-I and Class-II restricted T cell responses [55-57].
In liver biopsies, the liver schizonts from immunized
chimpanzees were surrounded by a large granuloma
containing macrophages, lymphocytes, granulocytes able
to release around the parasite, very high local concentra-
tions of IFN-g, and likely IFN-a [47].
Indications for the role of IFN-g in pre-erythrocytic
immunity in humans
Surprisingly, only indirect and fragmentary indications
of the role of IFN-g in malaria pre-erythrocytic immu-
nity have been gathered in humans. A first observation
is that attenuated P. falciparum sporozoites as well as
subunit vaccines elicit IFN-g-producing CD4+ and CD8+
T cells (reviewed in [51,58]). The production of IFN-g by
LSA3 specific T cells was observed in each of three
volunteers who were protected following immunization
with irradiated sporozoites. However, in contrast with
the chimpanzee model, no negative control, similarly
immunized but non-protected, is available to assess the
predictive value of those IFN-g responses. More recently,
volunteers could be protected by exposure to non-
irradiated sporozoites under chloroquine treatment.
Strong IFN-g–producing T cells were observed in all
immunized volunteers, whereas antibody responses were
inconsistent, supporting the potential role of IFN-g pro-
ducing T cells in P. falciparum pre-erythrocytic immu-
nity [59]. However, the lack of a control group, similarly
immunized, but not protected, prevented the establish-
ment of any causal relationship between the levels of
IFN-g and the observed protection here also.
Correlations of P. falciparum antigen specific CD4+
T-cell responses with resistance to malaria in humans
have been reported [4]. In studies with CS protein and
ME-TRAP vectored vaccines, which induced partial pro-
tection (ie. a patency delay) antibody levels induced by
this regime were low or absent and were not associated
with protection (reviewed in [49]). However, using ex
vivo a n dc u l t u r e dI F N - g ELISPOT assays, which mea-
sure mainly effector and central memory T cells respec-
tively, only the latter showed an association with
protection [60,61]. Surrogates were also searched for
among the various cohorts immunized by RTSS, show-
ing transient protection. One study identified among
individuals without blood parasites for 100 days, a sig-
nificantly higher frequency of individuals secreting IFN-
g in response to a CS peptide, than of non-responding
individuals [62], whereas several other studies found a
correlation with antibody responses (reviewed in [4]).
In malaria endemic areas, populations are exposed to
a large variety of other infections, particularly of viral
origin. It was reasoned that viral infections could induce
substantial levels of IFN-g and this situation could be
used as a clue to address the role of IFN-g on the hepa-
tic cycle in vivo in humans. Indeed, a first study showed
high serum levels of IFN-g, since among 106 individuals
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70 IU/ml [63]. This subsequently led to the conduction
of two immuno-epidemiological studies. The first
described a significant correlation between pre-existing
serum IFN-g levels and susceptibility to new malaria
blood infections, i.e. the successful transhepatic passage
of the parasite [64]. In the second, a very significant dif-
ference in time to first infection, i.e. protection, was also
observed depending on the ability of patient’s lympho-
cytes to secrete IFN-g in response to LSA1 antigen [65].
Both observations document the influence of IFN-g
upon the success of exposure to sporozoites in humans.
Additional indirect evidence for CD8+ T cell derived
IFN-g comes from the association of the HLA-Bw53
allele with protection [66] as well as class I restricted
responses to the LSA3 and PfExp-1 antigens [67]. How-
ever, these indications were not confirmed in another
location, nor by a parasitological re-assessment of the
initial finding [68].
Discussion
Results gathered in primates challenged by P. falciparum
and, to some extent, in humans, point to interferon-g as a
possible immune mediator or at least a surrogate marker
significantly associated with protection against
P. falciparum and actually, the only surrogate available
to-date.
Despite the high genetic similarity (up to 99.4%) between
chimpanzee and humans, the remaining differences limit
the scope of these results obtained in these higher pri-
mates, with only indirect indications that the same holds
true in humans. A second limitation is that most of the
results concern immunity induced by LSA3, even though
there are indications that the same holds true for humans
immunized by irradiated sporozoites, or by other pre-
erythrocytic antigen vaccine candidates. Thus data
obtained in primates point clearly to IFN-g as a reliable
surrogate of protection, whereas data obtained in humans,
in the field or in vaccine trials, is in-keeping with this con-
clusion, however without demonstrating it as clearly [4,58].
It is extremely striking and shocking that the most
critical data, which could have been acquired in human
volunteers immunized by irradiated sporozoites, is lacking.
This is most regrettable, and surprising, considering the
massive amounts of funding devoted to pre-erythrocytic
vaccines at large. It does not seem reasonable to continue
to evaluate the potential of a large number of vaccine for-
mulations in lengthy and costly phase I and phase II field
trials, while the identification of immune effectors or a
reliable surrogate marker of protection associated with
protection against P. falciparum pre-erythrocytic stages is
close at hand, yet is not searched for.
Indeed, the opportunity exists for a rational approach
in the development of malaria pre-erythrocytic stage
vaccines by the identification of the relevant mechanism
(s) of protection through clinical experiments with irra-
diated sporozoite immunization. Complete protection is
achieved by vaccination with optimally irradiated sporo-
zoites (15-18 kRad), whereas vaccination with over-
irradiated sporozoites (23-30 kRad) induces strong
immune responses but no protection [69]. This constitu-
tes a very discriminative situation best fitted to identify
either the critical mechanisms involved, or a surrogate
marker of protection (such as a certain level of IFN-g).
There have been to-date more than 1400 volunteers
challenged by P. falciparum to assess in humans experi-
mental vaccines that were designed in models [70], the
majority of which failed to induce protection. In con-
trast, there have been less than two dozen volunteers
immunized by irradiated sporozoites [69]. Arguably the
available and unique irradiated sporozoite model has
remained largely underexploited for the last two dec-
ades, and disconcertingly it still does not seem to attract
much interest. Despite the very high failure rate of clini-
cal trials, the current vaccine development strategy con-
tinues, by and large, in an empirical manner.
Studies with P. falciparum in primates do not bring
much support to the role of antibody (Abs) responses in
protection against malaria pre-erythrocytic stages, in
contrast to what was suggested by numerous experi-
mental studies and which was emphasized in many
reviews. The antibody-mediated detachment of the spor-
ozoite surface (circumsporozoite precipitation) and anti-
body titration in rodents have been considered for a
long time as evidence for a major, if not sole, role of
antibodies in protection [9]. Further work conducted
in vitro in primary hepatocyte cultures has indicated a
strong sporozoite-invasion inhibitory effect by antibodies
both for rodent and for human malaria. This was shown
to be true for Abs specific to a wide range of antigens
such as CS [71,72], STARP [73], LSA3 [74], SALSA
(Pasqueto, V. and Druilhe, P. unpublished data), TRAP
[75], AMA-1 [76] as well as when using African adults
sera which contain a wide range of antibody specificities
[13]. Sporozoite invasion inhibition was also confirmed
by in vivo passive transfer experiments [77,78]. In addi-
tion it was also shown that Abs could promote the
opsonization of sporozoites by macrophages [10]. Yet,
despite the wide range of evidences in various models,
results from P. falciparum challenges do not bring sup-
port for a critical role of Abs as an effector or a
surrogate.
In contrast, for IFN-g, data gathered using rodent
Plasmodium species, despite the limitations of models
and the diversity of protective mechanisms involved,
are nonetheless in keeping with data obtained with
P. falciparum.T h es t r o n ge f f e c to fI F N - g upon liver
schizogony was documented in all rodent plasmodia
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yoelii, Plasmodium chabaudi and Plasmodium vinckei)
in various strains of mice [20,27,34,36,79]. The studies
conducted in models stressed the effect of each compo-
nent of the cascade going from IL12 to nitric oxyde.
Indeed the potent effect of IL12 [33] is logical as it leads
nonT and nonB cells to secrete IFN-g. The role of IFN-g
itself is the most documented by numerous independent
studies [20,34,35], including using IFN-g receptor
knockout animals, which failed to be protected by irra-
diated sporozoites [36]. The involvement of NO
synthase, downstream of the IFN-g signalling, has been
well documented, as well as the direct effect of NO-
radicals [33,38,79,80]. Thus studies with rodent species
led to dissect this pathway as essential in defence against
malaria liver stage (LS), regardless of the target species
used.
Observations in situ showing a large granuloma
around P. falciparum liver schizonts in protected chim-
panzees [47] have also been analysed and modellized in
mice [80]. In those experiments, intra-portal delivery of
microparticles coated with P. falciparum liver stage pep-
tide epitopes induced strong local cellular infiltrates.
This intra-hepatic cellular response detected in mice
around the parasite’s epitope coated microparticles clo-
sely mimics the granuloma detected around chimpan-
zees’ liver schizonts. These immune infiltrates were
made up of PMN, MO, dendritic cells, but most impor-
tantly of IFN-g producing activated CD4+ and to a les-
ser extent CD8+ T-cells, suggesting a Th1 type local
immune response [80]. Using different schemes of immu-
nization, the size of intra-hepatic cellular infiltrate was
recently found to correlate with the level of protection
(Perlaza et al, unpublished data). Indeed, immunization
schemes that induced better protective immunity were
associated with the strongest local IFN-g-producing
T cell responses. In addition, kinetic studies indicated
that, following PMN recruitment, CD4+ T-cells are the
first to migrate into the liver toward the parasite anti-
gens. Although in humans the situation is less clear,
several indications point more to Th1 CD4+ cells,
rather than CD8+ T cells, as the most critical cell type
involved in IFN-g secretion [49]. Production of IFN-g by
PBMC in response to liver stage antigens was also asso-
ciated with resistance to re-infection with P. falciparum
in young African children [65]. Vaccine formulations,
such as microparticles and lipopeptides, delivered with-
out adjuvant, which proved protective in non-human
primates, also induced mainly type-1 CD4+ T cell (Th1)
responses but only a low level of CD8+ T cells
responses. Finally, in mice, it was previously found that
adoptive transfer of parasite-epitope specific Th1 clones,
but not Th2 clones, protected mice against a sporozoite
challenge [65].
Hence, the combination of data, from both humans
and non-human primates, support that protective
immunity against P. falciparum liver stages is associated
with induction of local intra-hepatic helper-type 1 CD4+
T cells that secrete high levels IFN-g. This suggests that
a successful malaria vaccine strategy and formulation
should, therefore, promote the induction of strong IFN-
g-producing CD4+ cell responses.
Conclusions
I nc o n c l u s i o n ,i tw a st h o u g h tt ob eu s e f u lt or e p o r t
these data, whatever their limitations, at least as an
incentive to trigger the implementation of further simi-
lar investigations in human beings the absence of which
is most surprising and appears to be a missed opportu-
nity. Undoubtedly, if there was a protocol able to induce
sterile protection against, for instance, HIV infection in
humans, as there is with irradiated sporozoites in
malaria, this would probably be immediately exploited
to analyse the mechanisms and antigens involved. Why
this has not and is still not implemented for the pre-ery-
throcytic stages of malaria remains a mystery. It would
seem that limited clinical trials in relatively small groups
of volunteers immunized either by optimally irradiated
or over-irradiated sporozoites could help delineate sur-
rogate markers of protection, and thereby contribute to
the development of a powerful rationale, which is funda-
mentally required for the development of a successful
pre-erythrocytic stage vaccine, and which is currently
lacking.
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